The Role of Adipose Derived Mesenchymal Stem Cells (MSCs) to Control Autoimmune Disease

Abstract

There are 80 types of autoimmune diseases (ADs) with some of the same symptoms, but causes are still unclear. The major treatment of ADs is immunosuppressive drugs but these are not effective and associated with substantial toxicities. Stem cell has demonstrated remarkable effectiveness in halting destructive immune response and restoring the body to level of normal function by providing cellular level repair of damage, increasing blood flow, and reducing inflammation. Adipose tissue is one of the most potent and concentrated source of mesenchymal stem cells (MSCs) as an anti-inflammatory and tissue protecting agent which is promote healing and minimal invasive. This study conducted in 20 patients with ADs (11 women and 9 men) in various age between 22 to 70 years old. Patients treated with autologous adipose-derived MSCs implantation through catheterization. The laboratory analysis result of patients before and after MSCs application in 6 months were measured, include haemoglobin (Hb), leukocytes, erythrocyte sedimentation rate (ESR), protein and blood levels in urine, high sensitivity c-reactive protein (hsCRP), C3 and C4 complement, anti-nuclear antibodies (ANA) and anti-double stranded DNA (anti-dsDNA). MSCs are able to improve the performance of hemoglobin which statistically significant increased (p=0.002). MSCs are able to reduce the inflammatory as shown in the number of leukocytes (p=0.015) and ESR (p=0.031) which statistically significant decreased. MSCs can repair the renal function as shown in no presences of protein and blood in patient’s urine. MSCs are also able to augment the immune response as shown in hsCRP which statistically significant decreased (p<0.001), while C3 and C4 complements statistically significant increased (p<0.001). ANA and anti-dsDNA showed a negative result which means MSCs therapy may give a good response to heal the ADs.

Application of Baculovirus Expression Vector System (BEVS) in Vaccine Development

“…Jin Sun et al designed two vaccines, cE80 (D4) and cE80 (max), which can stimulate specific antibodies against all four medium Dengue virus (DENV) serotypes in mice, mainly activating IgG1. In addition, they can activate type I and type II antigen-specific helper T cells that secrete IFN-γ and IL-4, respectively, which are currently in the preclinical phase [90,91]. In addition, many BEVS-derived vaccines for SARS-CoV-2 variants are in the preclinical phase.…”